Imagia Canexia Health

Imagia Canexia Health (ICH) is a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions. Leveraging AI-based informatics for treatment selection and monitoring, oncologists now have leading clinical decision support right at their fingertips. With a network of over 20 hospitals and reference labs worldwide, ICH ensures that doctors have the right insights to deliver cost-effective cancer testing to patients no matter where they seek treatment.

ICH's goal of closing the health-equity gap in cancer is reflected in its slogan, "Closing the health-equity gap in cancer." Its establishment in 2022 positions it as a newcomer in the genomics-based cancer treatment industry. Although specific information about its headquarters or recent investments and investors is not available, the company's focus on leveraging AI for precision care presents a promising opportunity for potential venture capital interest.